1 Min Read
* Alere receives FDA clearance for Alere I Influenza A & B 2 rapid molecular test
* Alere Inc says will shortly submit an application for CLIA waiver of Alere i Influenza A & B 2 test Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.